Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $17.25.
ENTA has been the topic of a number of recent analyst reports. StockNews.com upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. Robert W. Baird dropped their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating on the stock in a report on Tuesday, November 26th. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, JMP Securities reissued a "market outperform" rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th.
Read Our Latest Stock Analysis on ENTA
Shares of NASDAQ ENTA opened at $6.77 on Tuesday. The business has a 50-day moving average of $6.10 and a 200-day moving average of $8.79. The stock has a market capitalization of $144.42 million, a price-to-earnings ratio of -1.37 and a beta of 0.48. Enanta Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $17.80.
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. On average, sell-side analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current year.
In other news, CEO Jay R. Luly purchased 45,000 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The stock was acquired at an average cost of $5.69 per share, with a total value of $256,050.00. Following the acquisition, the chief executive officer now owns 846,638 shares in the company, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.89% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the company. US Bancorp DE grew its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 4,243 shares in the last quarter. Quest Partners LLC grew its position in shares of Enanta Pharmaceuticals by 65.0% during the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company's stock worth $198,000 after purchasing an additional 7,535 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $122,000. Valence8 US LP bought a new position in shares of Enanta Pharmaceuticals during the third quarter worth approximately $207,000. Finally, FMR LLC raised its position in shares of Enanta Pharmaceuticals by 18.9% in the third quarter. FMR LLC now owns 49,301 shares of the biotechnology company's stock valued at $511,000 after buying an additional 7,839 shares in the last quarter. Institutional investors own 94.99% of the company's stock.
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Enanta Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.
While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.